KAMADA » INVESTORS

INVESTMENT HIGHLIGHTS

  • Rapidly Growing, Globally Positioned Biopharmaceutical Company
    - Focused on Orphan Diseases and Plasma Derived Protein Therapeutics
     
  • Flagship Product Glassia® Approved for Alpha-1 Antitrypsin Deficiency Disorder
    - Has a Unique and Differentiated Product Profile and Represents an Exciting Growth Opportunity
     
  • Significant Opportunity in Novel Inhaled AAT Undergoing Pivotal Clinical Development
     
  • Validating Strategic Partnerships with Industry Leaders Baxter, Chiesi, Kedrion and Pari Pharma
     
  • Valuable R&D Pipeline Focused on Various Orphan Indications
     
  • Integrated, Efficient and Scalable Best-in-class Patented Platform Technology and Know-How
     
  • Strong Financial Profile with Increasing Profitability

LATEST NEWS

Kamada Announces Withdrawal of European Marketing Authorization Application for Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency Disease

Jun. 27, 2017

Kamada announced that the Company has withdrawn the Marketing Authorization Application (MAA) for its proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD) with the European Medicines Agency (EMA).

Kamada Receives Additional Milestone Payment Under GLASSIA® Exclusive Supply and Distribution Agreement with Shire

Jun. 12, 2017

Kamada announced the receipt of an undisclosed additional milestone payment under the supply and distribution agreement with Shire for GLASSIA®, Kamada’s intravenous (IV) alpha-1 antitrypsin (AAT).

More News

FINANCIAL REPORTS

Q1 / 2017 Financial Report

Jun. 22, 2017

Annual Report 2016

Dec. 31, 2016

Q3 / 2016 Financial Report

Nov. 10, 2016

More Reports

STOCK QUOTE

NASDAQ

KMDA:$5.925
Change:-3.66%
Date & Time:6/27/2017 3:59pm
For more information: KAMADA on NASDAQ website

TASE

Share price                                             Daily volume(NIS)                

Click here for more information 

 Convertible bond                                  Daily volume(NIS)

Click here for more information

 For more information: KAMADA on Tel- Aviv Stock Exchange website

CORPORATE GOVERNANCE

Please click "Read more" to view Kamada's Corporate Governance items.

Read more

IR CONTACT & FAQ

Gil Efron
CFO
ir@kamada.com

Bob Yedid
LifeSci Advisors
646-597-6989
bob@lifesciadvisors.com

 

Read more